Gerresheimer AG (GXIG)

Currency in EUR
25.920
-0.380(-1.44%)
Closed·
GXIG is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
25.80026.560
52 wk Range
14.83046.720
Key Statistics
Prev. Close
25.86
Open
26.56
Day's Range
25.8-26.56
52 wk Range
14.83-46.72
Volume
99.91K
Average Volume (3m)
198.21K
1-Year Change
-43.3814%
Book Value / Share
31.3
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GXIG Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
27.045
Upside
+4.34%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Gerresheimer AG News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

2 Buy
7 Hold
3 Sell
Ratings:
12 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 27.045
(+4.34% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
UBS
Hold28.50+9.95%12.90UpgradeAug 05, 2026
Deutsche Bank
Hold26.00+0.31%22.00MaintainAug 04, 2026
Barclays
Sell25.00-3.55%17.00MaintainJul 30, 2026
Barclays
Sell17.00-34.41%19.00MaintainJul 07, 2026
Berenberg
Hold24.00-7.41%20.00MaintainJul 02, 2026

Gerresheimer AG Earnings Call Summary for Q4/2025

  • Gerresheimer reported €2.3B revenue (+€330M YoY) but only 0.3% organic growth, with adjusted EBITDA flat at €384M and negative €86M free cash flow.
  • Shares fell 3.47% to $25.06 as investors focused on weak cash generation, high 4.95x debt leverage, and €1.65 EPS loss despite completing compliance cleanup.
  • Primary Packaging Glass segment remained under pressure from lower volumes and plant issues; syringes/medical devices grew on GLP-1 demand and new project ramps.
  • Management expects 2026 revenue at lower half of €2.3-2.4B range, EBITDA margin of 17-18%, but negative €50-100M free cash flow excluding Centor sale proceeds.
  • CEO prioritized selling Centor by November 2026 and completing debt refinancing with Lazard; transformation program expected to add €10-20M EBITDA in 2026.
Last Updated: 29/06/2026, 15:08
Read Full Transcript

Earnings

Latest Release
Jul 30, 2026
EPS / Forecast
-0.12 / 0.41
Revenue / Forecast
499.01M / 513.95M
EPS Revisions
Last 90 days

GXIG Income Statement

Compare GXIG to Peers and Sector

Metrics to compare
GXIG
Peers
Sector
Relationship
P/E Ratio
−2.8x17.8x−0.4x
PEG Ratio
0.010.020.00
Price/Book
0.8x1.7x2.6x
Price / LTM Sales
0.4x1.2x3.1x
Upside (Analyst Target)
−1.4%14.4%48.2%
Fair Value Upside
Unlock9.9%5.8%Unlock

Gerresheimer AG, together with its subsidiaries, provides drug containment solutions in Germany and internationally. The company operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. It offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and containers, bottles, caps, closures, applicators, and accessories; development, industrialization, and contract manufacturing of drug delivery programs; project and quality management; and drug delivery devices, including inhalers, injection/auto injectors, and pen injectors. The company also provides diagnostic and medical devices comprising point-of-care tests, laboratory disposables, chemical and technical bottles, diagnostic and polymer vials, dropper bottles, PET bottles, and medical products comprising lancing devices, infusion sets, and disposable systems. In addition, it offers cosmetic packaging solutions, such as moulded glass flacons and jars; tubular glass ampoules, droppers, samplers and vials; and plastic packaging products, as well as pharmaceutical, laboratory, and regulatory affairs services. The company offers its products to pharmacy chains, supermarkets, and wholesalers. The company serves pharma, biotech, medical technology, diagnostics, cosmetics, glass containers, and food and beverage industries. Gerresheimer AG was founded in 1864 and is based in Düsseldorf, Germany.

Employees
13528
Market
Germany

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
8.55M24.76%221.65M
Other Institutional Investors
20.73M60.00%537.19M
Public Companies & Retail Investors
5.26M15.24%136.43M
Total
34.54M100.00%895.28M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
The Goldman Sachs Group, Inc.11.89%4,106,480106,440
Goldman Sachs Asset Management, L.P.8.75%3,021,12978,308

People Also Watch

40.470
AIXGn
+0.90%
57.550
EVDG
-2.04%
101.20
KBX
-0.69%
6.71
TMV
+2.60%
60.900
NEKG
+0.50%

FAQ

What Is the Gerresheimer AG (GXIG) Stock Price Today?

The Gerresheimer AG stock price today is 25.920 EUR.

What Stock Exchange Does Gerresheimer AG Trade On?

Gerresheimer AG is listed and trades on the Frankfurt Stock Exchange.

What Is the Stock Symbol for Gerresheimer AG?

The stock symbol for Gerresheimer AG is "GXIG."

What Is the Gerresheimer AG Market Cap?

As of today, Gerresheimer AG market cap is 895.280M EUR.

What Is Gerresheimer AG's Earnings Per Share (TTM)?

The Gerresheimer AG EPS (TTM) is -9.274.

When Is the Next Gerresheimer AG Earnings Date?

Gerresheimer AG will release its next earnings report on Oct 01, 2026.

From a Technical Analysis Perspective, Is GXIG a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Gerresheimer AG Stock Split?

Gerresheimer AG has split 0 times.

How Many Employees Does Gerresheimer AG Have?

Gerresheimer AG has 13528 employees.

What is the current trading status of Gerresheimer AG (GXIG)?

As of Aug 11, 2026, Gerresheimer AG (GXIG) is trading at a price of 25.920 EUR, with a previous close of 25.860 EUR. The stock has fluctuated within a day range of 25.800 EUR to 26.560 EUR, while its 52-week range spans from 14.830 EUR to 46.720 EUR.

What Is Gerresheimer AG (GXIG) Price Target According to Analysts?

The average 12-month price target for Gerresheimer AG is 27.045 EUR, with a high estimate of 46 EUR and a low estimate of 12.5 EUR. 2 analysts recommend buying the stock, while 3 suggest selling, leading to an overall rating of Neutral. The stock has an +4.34% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.